InnovAntiBiofilm Boosting Sustainable Innovation in Developing New Antibiotic Adjuvants to Control Biofilm Resistance
- Coordinator
- Universidade Do Porto, Portugal
- Runs
- 1 October 2024 to 30 September 2027
- Status
- Running
- EU funding
- €1.5m
- Total cost
- —
- Partners
- 4 organisations in 3 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101157363
What the project is doing
In the project's own words, from its summary on CORDIS.
InnovAntiBiofilm will revolve around the subject matter of sustainable development of new adjuvant agents to boost the action of antibiotics against biofilm infections. This will be achieved through the sustainable biosynthesis of plant molecules and the rational development of derivatives. These scientific activities, together with capacity building and networking activities, talent development of young researchers, mentoring, inclusiveness, and strengthening research management and administration skills, will be at the crux of the project concept.
This will be achieved by Twinning UPORTO with truly outstanding EU institutions with recognised expertise in the areas of medicinal and combinatorial chemistry (CEA), metabolic and bioprocess engineering (Fraunhofer-IME), and R&I management, access to funding and links with industry (KPMG). These internationally-leading partners will provide decisive expertise to capacitate UPORTO on the heterologous biosynthesis of phytochemicals and development of innovative phytochemical derivatives with improved antibiotic adjuvant action for biofilm control, as well as to strengthen UPORTO’s R&D competitiveness and administrative skills.
The objectives of InnovAntiBiofilm are in line with the specific challenge and scope of the topic HORIZON-WIDERA-2023-ACCESS-02-01 of the Twinning call, addressing networking gaps and deficiencies between the research institutions of the Widening countries and internationally-leading counterparts at EU level. InnovAntiBiofilm will allow the development of a consolidated strategic research approach and a set of guidelines for exploitation and commercialisation of the results that will have a strong regional, national and European impact.
The project integrates synergies in complementary fields of research that include biotechnology, microbiology, synthetic chemistry and pharmacognosy, aiming to obtain scientific breakthroughs that can improve global health and economy.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universidade Do Porto | Porto | Portugal | Coordinator |
| Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung eV | Munchen | Germany | Participant |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Participant |
| Kpmg & Associados Sociedade De Revisores Oficias De Contas SA | Lisbon | Portugal | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI